1. |
Yoo CB, Jones PA. Epigenetic therapy of cancer:past, present and future[J]. Nat Rev Drug Discov, 2006, 5(1):37-50.
|
2. |
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors[J]. Nat Rev Drug Discov, 2006, 5(9):769-784.
|
3. |
Huang C, Sloan EA, Boerkoel CF. Chromatin remodeling and human disease[J]. Curr Opin Genet Dev, 2003, 13(3):246-252.
|
4. |
Shabason JE, Tofilon PJ, Camphausen K. HDAC inhibitors in cancer care[J]. Oncology (Williston Park), 2010, 24(2):180-185.
|
5. |
Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer[J]. Nat Rev Cancer, 2006, 6(1):38-51.
|
6. |
Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma[J]. Drugs Today, 2007, 43(9):585-599.
|
7. |
李虎群, 余聂芳. 组蛋白去乙酰化酶抑制剂抗肿瘤作用机制研究进展[J]. 中国医药指南, 2011, 9(6):47-48.
|
8. |
李晓晖, 李建勋, 李世荣, 等. 环肽类组蛋白去乙酰化酶抑制剂[J]. 化学进展, 2007, 19(5):762-768.
|
9. |
Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary:vorinostat for treatment of advanced primary cutaneous T-cell lymphoma[J]. Oncologist, 2007, 12(10):1247-1252.
|
10. |
Noh EJ, Lim DS, Jeong G, et al. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner[J]. Biochem Biophys Res Commun, 2009, 378(3):326-331.
|
11. |
楼文珠, 孙雪燕, 李龙珠, 等. 组蛋白脱乙酰酶抑制剂的抗癌作 用[J]. 中国细胞生物学学报, 2011(9):1045-1052.
|
12. |
Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells[J]. Int J Cancer, 2007, 121(3):656-665.
|
13. |
Crump M, Coiffier B, Jacobsen ED, et al. Phase Ⅱ trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma[J]. Ann Oncol, 2008, 19(5):964-969.
|
14. |
Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase Ⅱ trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer[J]. Invest New Drugs, 2008, 26(5):483-488.
|
15. |
Blumenschein GJ, Kies MS, Papadimitrakopoulou VA, et al. PhaseⅡtrial of the histone dea cetylase inhibit or vorinostat (Zolinz, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer[J]. Invest New Drugs, 2008, 26(1):81-87.
|
16. |
杜晓琅, 朱贺, 丁黎, 等. 液相色谱-串联质谱法同时测定人血清与尿液中伏立诺他及其代谢物4-苯胺基-4-氧代丁酸的浓度[J]. 中国新药与临床杂志, 2012, 31(7):385-391.
|
17. |
Du L, Musson DG, Wang AQ. High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum[J]. Rapid Commun Mass Spectrom, 2005, 19(13):1779-1787.
|
18. |
Parise RA, Holleran JL, Beumer JH, et al. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2006, 840(2):108-115.
|